Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

@article{Roffi2001PlateletGI,
  title={Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.},
  author={Marco Roffi and Derek P B Chew and Debabrata Mukherjee and Deepak L Bhatt and Jennifer A. White and Christopher Heeschen and C. W. Hamm and David J Moliterno and Robert M. Califf and Harvey Douglas White and Neal S. Kleiman and Pierre Th{\'e}roux and Eric J. Topol},
  journal={Circulation},
  year={2001},
  volume={104 23},
  pages={2767-71}
}
BACKGROUND Diabetes mellitus is a major risk factor for adverse outcomes after acute coronary syndromes (ACS). Because this disease may be associated with increased platelet aggregation, we investigated whether diabetic patients with ACS derive particular benefit from platelet glycoprotein (GP) IIb/IIIa receptor inhibition. METHODS AND RESULTS We performed a meta-analysis of the diabetic populations enrolled in the 6 large-scale platelet GP IIb/IIIa inhibitor ACS trials: PRISM, PRISM-PLUS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
127 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 127 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…